Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02478450
Recruitment Status : Not yet recruiting
First Posted : June 23, 2015
Last Update Posted : March 18, 2019
Sponsor:
Information provided by (Responsible Party):
Q Therapeutics, Inc.

Tracking Information
First Submitted Date  ICMJE June 11, 2015
First Posted Date  ICMJE June 23, 2015
Last Update Posted Date March 18, 2019
Estimated Study Start Date  ICMJE December 2020
Estimated Primary Completion Date December 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 18, 2015)
Safety of human glial restricted progenitor cell transplantation in patients with Amyotrophic Lateral Sclerosis. (adverse events) [ Time Frame: 9-month ]
Safety will be measured by the number of therapy related adverse events.
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT02478450 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: October 11, 2016)
  • Score on the amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) [ Time Frame: 9-month ]
  • Quantitative muscle strength values from a hand held dynamometer (HHD) will be tested bilaterally [ Time Frame: 9-month ]
  • Hand grip (bilateral) values from a grip dynamometer [ Time Frame: 9-month ]
  • Forced vital capacity (FVC) [ Time Frame: 9-month ]
  • Maximum sniff nasal inspiratory pressure (SNIP) [ Time Frame: 9-month ]
  • Electrical Impedance Myography (EIM) values on bilateral upper and lower limbs [ Time Frame: 9-month ]
  • Pain scores on the Visual Analog Scale (VAS) [ Time Frame: 9-month ]
  • Score on the ALS Specific Quality of Life Questionnaire - Revised [ Time Frame: 9-month ]
  • Score on the Ashworth Spasticity Scale [ Time Frame: 9-month ]
Original Secondary Outcome Measures  ICMJE
 (submitted: June 18, 2015)
  • Score on the amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) [ Time Frame: 9-month ]
  • Quantitative muscle strength values from a hand held dynamometer (HHD) will be tested bilaterally [ Time Frame: 9-month ]
  • Hand grip (bilateral) values from a grip dynamometer [ Time Frame: 9-month ]
  • Forced vital capacity (FVC) [ Time Frame: 9-month ]
  • Maximum sniff nasal inspiratory pressure (SNIP) [ Time Frame: 9-month ]
  • Maximum inspiratory pressure (MIP) [ Time Frame: 9-month ]
  • Electrical Impedance Myography (EIM) values on bilateral upper and lower limbs [ Time Frame: 9-month ]
  • Pain scores on the Visual Analog Scale (VAS) [ Time Frame: 9-month ]
  • Score on the ALS Specific Quality of Life Questionnaire - Revised [ Time Frame: 9-month ]
  • Score on the Ashworth Spasticity Scale [ Time Frame: 9-month ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS)
Official Title  ICMJE A Phase 1/2a Open-Label Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS): Assessment of Localized Therapeutic Activity by Blinded Observation and Lateral Transplantation (ALTA-BOLT)
Brief Summary This study is a non-randomized, open-label, partially blinded, sequential cohort, dose-escalation study designed to obtain preliminary data on the safety, tolerability, and early efficacy of Q-Cells® transplantation in subjects with ALS. Following an initial cohort receiving cell transplants unilaterally in the lumbar spinal cord, subsequent cohorts will receive escalating doses transplanted unilaterally in cervical spinal cord. Subjects and outcome measure assessors will be blinded to side of treatment. The study will be conducted at sites with extensive clinical experience with the care of patients with ALS.
Detailed Description

This study is a non-randomized, open-label, partially blinded, sequential cohort, dose-escalation study designed to obtain preliminary data on the safety, tolerability, and early efficacy of Q-Cells® transplantation in subjects with ALS. Following an initial cohort receiving cell transplants unilaterally in the lumbar spinal cord, subsequent cohorts will receive escalating doses transplanted unilaterally in cervical spinal cord. Subjects and outcome measure assessors will be blinded to side of treatment. The study will be conducted at sites with extensive clinical experience with the care of patients with ALS.

The study is planned to enroll up to 30 subjects over 24 months. Each subject will receive a single time point administration of Q-Cells®: with 5 or 10 (dependent upon dose level) transplantation foci targeted to the anterior horn in either the lumbar or cervical spinal cord.

The study consists of Screening, Pre-operative/Treatment, and Post-treatment study periods. The study data will be assessed for safety and efficacy after the last subject has completed the 9-month study visit. Following the 9-month study period, subjects who consent will continue to be followed for safety and efficacy long-term in a separate protocol.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Amyotrophic Lateral Sclerosis
Intervention  ICMJE Biological: Q-Cells
cellular therapeutic comprised of human cells of the glial lineage
Other Name: glial restricted progenitor cells
Study Arms  ICMJE
  • Experimental: Cohort 1
    Unilateral lumbar surgical transplantation of Q-Cells dose level 1
    Intervention: Biological: Q-Cells
  • Experimental: Cohort 2
    Unilateral cervical surgical transplantation of Q-Cells dose level 1
    Intervention: Biological: Q-Cells
  • Experimental: Cohort 3
    Unilateral cervical surgical transplantation of Q-Cells dose level 2
    Intervention: Biological: Q-Cells
  • Experimental: Cohort 4
    Unilateral cervical surgical transplantation of Q-Cells dose level 3
    Intervention: Biological: Q-Cells
  • Experimental: Cohort 5
    Unilateral cervical surgical transplantation of Q-Cells dose level 4
    Intervention: Biological: Q-Cells
  • Experimental: Cohort 6
    Unilateral cervical surgical transplantation of Q-Cells dose level 5
    Intervention: Biological: Q-Cells
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: October 11, 2016)
30
Original Estimated Enrollment  ICMJE
 (submitted: June 18, 2015)
12
Estimated Study Completion Date  ICMJE December 2023
Estimated Primary Completion Date December 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Subject has the ability to understand the purpose and risks of the study and provide a signed and dated informed consent and authorization to collect and use protected health information (PHI) in accordance with national and local subject privacy regulations.
  2. Subject lives within reasonable driving distance of study center (approximately 3 hours).
  3. Subject has a caregiver willing/able to assist in the transportation and care required by study participation.
  4. Subject is 18 - 80 years of age (inclusive) on the first day of the Screening Period.
  5. Subject is diagnosed with sporadic or familial ALS within the past 48 months.
  6. Subject meets the laboratory-supported probable, clinically probable, or definite criteria for diagnosing ALS according to the World Federation of Neurology El Escorial criteria.
  7. Subject has an upright FVC ≥65% of predicted value for age, height, and gender at Screening.
  8. Subject has not taken riluzole for at least 30 days prior to the first day of the Screening Period, or has been on a stable dose of riluzole for at least 30 days prior to the first day of the Screening Period (Riluzole-naïve subjects are permitted in the study).
  9. Subject is medically able to undergo the study procedures and physically able to adhere to the visit schedule at the time of study entry.
  10. Women of childbearing capacity must have a negative pregnancy test during the Screening Period and at the Pre-Operative Visit.
  11. Subject must agree to practice effective birth control during study participation.

Exclusion Criteria:

  1. Subject in whom causes of neuromuscular weakness other than ALS have not been practically excluded.
  2. Subject with a diagnosis of significant cognitive impairment, clinical dementia, or major psychiatric illness including psychosis, bipolar disease, major depression, as determined by the DSM-V.
  3. Subject with a diagnosis of other neurodegenerative disease (e.g., Parkinson's disease, Alzheimer's disease).
  4. Subject with a diagnosis of any medical condition that impairs nerve or muscle function (e.g., notable peripheral neuropathy, metabolic muscle disease).
  5. Subject with a clinically significant history of unstable cardiac, pulmonary, renal, hepatic, endocrine, hematologic, or active malignancy or infectious disease or other medically significant illness, which, in the opinion of the Investigator, would preclude study participation.
  6. Subject with a history of spine surgery or anatomic variation incompatible with route of administration (as determined by neurosurgeon).
  7. Subject with severe cervical or lumbar stenosis, cord compression, or cervical or lumbar myelopathy.
  8. Subject with abnormal flow voids on the surface of the spinal cord suggestive of arteriovenous malformation (AVM).
  9. Subject demonstrating any evidence of CNS malignancy or CNS lesions as defined by imaging studies of the CNS (MRI of brain and spinal cord).
  10. Subject having uncontrolled hypertension (Systolic BP>180mmHg and/or Diastolic BP >110mmHg) or having a history of thrombotic events or poorly controlled medical conditions that, in the opinion of the Investigator and/or surgeon, increase risk of surgery.
  11. Subject who cannot undergo MRI examination because of the presence of a pacemaker, an implanted defibrillator or certain other implanted electronic or metallic devices, or who have been or might have been exposed to metal fragments, or any reason the subject cannot undergo an MRI routinely for the duration of the trial.
  12. Subject with clinically significant abnormal clinical laboratory values, as determined by the Investigator during the Screening Period.
  13. Subject who is immune compromised or who has a condition contraindicated to treatment with immunosuppression agents (e.g., tuberculosis, latent infection).
  14. Subject with an aspartate aminotransferase (AST) or alanine aminotransferase (ALT) value >3.0 times the upper limit of normal or creatinine >1.5 times the upper limit of normal and/or eGFR <50cc/min during the Screening Period.
  15. Subject with a history of alcohol or drug abuse or dependence within 1 year of the first day of the Screening Period, per DSM-V criteria.
  16. Subject unlikely to comply with study requirements, as determined by Investigator.
  17. Subject who has been exposed to any other experimental agent (off-label use or investigational) within 30 days of the first day of the Screening Period. Biologic agents may need additional time for washout and will be evaluated by the Sponsor on a case-by-case basis.
  18. Subject who has previously been administered stem cells.
  19. Subject with pre-existing anti-human leukocyte antigen (HLA) class I or class II antibodies directed against the Q-Cells®, as determined by panel reactive antibody (PRA) assay during the Screening Period.
  20. Subject with an allergy to Q-Cells® or any of its constituents (e.g., chicken eggs), or an allergy to any of the co-administered immunosuppressants or any of their excipients.
  21. Subject with any medical condition or using concomitant medication that would contraindicate the use of tacrolimus, mycophenolate mofetil, or prednisone as determined by Investigator.
  22. Subject with evidence of deep vein thrombosis (DVT) by venous ultrasound or any previous evidence of DVT.
  23. Subject who, in the opinion of the Investigator, has taken or is taking concomitant medications, supplements, or other agents that may interfere with the safety evaluation of Q-Cells® or may affect the course of the subject's ALS progression.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02478450
Other Study ID Numbers  ICMJE QALS-101
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Q Therapeutics, Inc.
Study Sponsor  ICMJE Q Therapeutics, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Q Therapeutics, Inc.
Verification Date March 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP